Kpcb Xv Associates, LLC Rapt Therapeutics, Inc. Transaction History
Kpcb Xv Associates, LLC
- $35.8 Million
- Q3 2022
A detailed history of Kpcb Xv Associates, LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Kpcb Xv Associates, LLC holds 648,531 shares of RAPT stock, worth $810,663. This represents 43.54% of its overall portfolio holdings.
Number of Shares
648,531
Previous 1,297,063
50.0%
Holding current value
$810,663
Previous $23.7 Million
34.08%
% of portfolio
43.54%
Previous 43.66%
Shares
3 transactions
Others Institutions Holding RAPT
# of Institutions
100Shares Held
124MCall Options Held
246KPut Options Held
69.6K-
Medicxi Ventures Management (Jersey) LTD22.4MShares$27.9 Million7.76% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA13.1MShares$16.4 Million3.39% of portfolio
-
Orbimed Advisors LLC San Diego, CA13.1MShares$16.4 Million0.56% of portfolio
-
Foresite Capital Management Vi LLC Larkspur, CA12.5MShares$15.6 Million8.8% of portfolio
-
Rtw Investments, LP New York, NY11.8MShares$14.7 Million0.3% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $37.1M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...